Flexion: Positive prelim data on knee osteoarthritis

 

• Findings from a Phase 1 single ascending dose trial indicate the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis (OA), was generally well-tolerated

• Two of five patients (40%) treated with FX201 in the low-dose, single ascending dose cohort reported substantial improvement in pain out to Week 24

• No evidence of systemic biodistribution of FX201 in plasma or shedding in urine or at the injection site was observed in any patient

• Longer term follow-up data from the low-dose cohort will be presented at ASGCT on May 11

https://finance.yahoo.com/news/flexion-therapeutics-announces-presentation-preliminary-113000413.html